Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.42 |
| ▸ | TK1 | P04183 | 6/20 | 0.41 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.40 |
| ▸ | TK2 | O00142 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21489369 | 0.88 | RNASE1 (0.50) | RNASE1POLBTYMSTK1NT5M | |
| Ammonia Solution, Strong SCHEMBL10491034 | 0.88 | RNASE1 (0.49) | RNASE1POLBTYMSTK1NT5M | |
| SCHEMBL7078317 | 0.87 | RNASE1 (0.44) | RNASE1POLBTYMSTK1TK2 | |
| Methane SCHEMBL8441491 | 0.85 | RNASE1 (0.48) | RNASE1POLBTYMSTK1TK2 | |
| SCHEMBL10491023 | 0.84 | RNASE1 (0.46) | RNASE1POLBTYMSTK1NT5M | |
| SCHEMBL6232615 | 0.83 | RNASE1 (0.42) | RNASE1TYMSTK1NT5MTK2 | |
| SCHEMBL6830771 | 0.83 | RNASE1 (0.51) | RNASE1TYMSTK1 | |
| SCHEMBL8591071 | 0.83 | RNASE1 (0.55) | RNASE1POLBTYMSTK1NT5M | |
| SCHEMBL10486964 | 0.82 | RNASE1 (0.45) | RNASE1TYMSTK1NT5MTK2 | |
| SCHEMBL6827418 | 0.82 | RNASE1 (0.53) | RNASE1TYMSTK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0948514-B1 | METHOD FOR THE SYNTHESIS OF NUCLEOTIDE OR OLIGONUCLEOTIDE PHOSPHORAMIDITES | ISIS PHARMACEUTICALS INC (US) | 2005-04-27 | — | — | EP | disclosed |
| US-20030013864-A1 | Method for the synthesis of nucleotide of oligonucleotide phosphoramidites | GRIFFEY RICHARD H (US) | 2003-01-16 | — | — | US | disclosed |
| US-6458941-B1 | RECOVERED FROM WASTE PRODUCTS OF OLIGONUCLEOTIDE BIOSYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-6441150-B1 | GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
| US-6103891-A | Method for the synthesis of nucleotide or oligonucleotide phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-15 | — | — | US | disclosed |
| US-5955600-A | Method for the synthesis of nucleotide or oligonucleotide phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013864-A1 | Method for the synthesis of nucleotide of oligonucleotide phosphoramidites | NUDT1, MTAP, PHOSPHO1 | RNASE1 374/4885POLB 59/4885TYMS 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.